Acadia Pharmaceuticals :
ACAD
ACAD
Stock Data
$27.15
$0.47 (1.76%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Acadia Pharmaceuticals Inc is a biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing innovative medicines for central nervous system disorders and rare diseases. Its flagship product, NUPLAZID, treats hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is also advancing treatments for conditions like Rett Syndrome, schizophrenia, Prader-Willi syndrome, and Alzheimer’s disease psychosis, among others. The company, originally named Receptor Technologies, was founded in 1993 and emphasizes addressing unmet medical needs in neuropsychiatric conditions.
All Acadia Pharmaceuticals Articles
77 Articles